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Abstract
Background: Curcumin (diferuloylmethane) shows significant activity across a wide spectrum of conditions, but its
usefulness is rather limited because of its low bioavailability. Use of nanoparticle formulations to enhance curcumin
bioavailability is an emerging area of research.
Methodology/Principal Findings: In the present study, curcumin-loaded apotransferrin nanoparticles (nano-curcumin)
prepared by sol-oil chemistry and were characterized by electron and atomic force microscopy. Confocal studies and
fluorimetric analysis revealed that these particles enter T cells through transferrin-mediated endocytosis. Nano-curcumin
releases significant quantities of drug gradually over a fairly long period, ,50% of curcumin still remaining at 6 h of time. In
contrast, intracellular soluble curcumin (sol-curcumin) reaches a maximum at 2 h followed by its complete elimination by
4 h. While sol-curcumin (GI50=15.6 mM) is twice more toxic than nano-curcumin (GI50=32.5 mM), nano-curcumin
(IC50,1.75 mM) shows a higher anti-HIV activity compared to sol-curcumin (IC50=5.1 mM). Studies in vitro showed that
nano-curcumin prominently inhibited the HIV-1 induced expression of Topo II a, IL-1b and COX-2, an effect not seen with
sol-curcumin. Nano-curcumin did not affect the expression of Topoisomerase II b and TNF a. This point out that nano-
curcumin affects the HIV-1 induced inflammatory responses through pathways downstream or independent of TNF a.
Furthermore, nano-curcumin completely blocks the synthesis of viral cDNA in the gag region suggesting that the nano-
curcumin mediated inhibition of HIV-1 replication is targeted to viral cDNA synthesis.
Conclusion: Curcumin-loaded apotransferrin nanoparticles are highly efficacious inhibitors of HIV-1 replication in vitro and
promise a high potential for clinical usefulness.
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Introduction
Curcumin, (diferuloyl methane) is a polyphenol obtained from the
rhizome of the herb Curcuma longa (turmeric). Curcumin has been
shown to exhibit anti-oxidant [1], anti-inflammatory [2], anti-
microbial [3] and anti-carcinogenic [4] activities. It also is hepato-
and nephro-protective [5,6], suppresses thrombosis [7], protects
against damage due to myocardial infarction [8] and exhibits hypo-
lipidemic [9] and anti-rheumatic activities [10]. Various animal
models and human studies have established that curcumin is
extremely safe even at very high doses (12 g/day). In spite of its
efficacy and safety, curcumin has not yet been utilized as a therapeutic
agent due to its limited bioavailability, a result of poor absorption, high
rate of metabolism and rapid systemic elimination [11]. Almost the
entire dose of orally administered curcumin is excreted in the faeces.
At high doses, the plasma contains nanomolar concentrations of the
parent compound and glucuronide together with sulfate conjugates
[12,13]. Enhanced bioavailability should bring this natural product to
the forefront of promising therapeutic agents.
Numerous approaches were tried earlier that aimed at improving
the bioavailability of curcumin. These include usage of adjuvants
which can block metabolic pathways of curcumin [14] and
encapsulation in liposomes or nanoparticles of various compositions
[15,16]. Though these delivery systems are biocompatible, they
mostly lack target specificity. In order to enhance specificity, many
drug-loaded materials are conjugated with apotransferrin/transfer-
rin proteins [17,18], which are abundantly expressed in actively
proliferating cells. Encapsulation with these proteins enables
preferential localization into target cells through receptor-mediated
endocytosis [19]. This apotransferrin nanoparticle-drug delivery
system also provides all the general advantages offered by nano-
formulations such as appropriate size for cellular uptake, excellent
water dispensability and improved intracellular localization. HIV-1
infected cells are known to express transferrin receptors, which bind
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These receptors could be targeted for ligand-mediated transport of
curcumin into the infected cells. In the present study, we formulated
curcumin-loaded apotransferrin nanoparticles (nano-curcumin)
using a sol-oil technique. These curcumin loaded nanospheres were
then assessed for their efficiency of cellular uptake and cytotoxicity
in T-cells. The nano-curcumin formulation was further evaluated
for its efficacy to inhibit HIV-1 replication. The results clearly
highlight the advantage of this delivery system over direct soluble-
curcumin administration.
Results
Preparation of curcumin-loaded apotransferrin
nanoparticles
Curcumin-containing apotransferrin nanoparticles were pre-
pared using sol-oil chemistry as described in materials and
methods section. Transmission electron microscopy (TEM)
analysis showed that the particles were nearly uniform in size
and spherical in shape. This technique also confirmed the increase
in diameter of loaded particles (Fig. 1A). The size of pure
apotransferrin nanoparticles as assessed by scanning electron
microscopy (SEM) ranged from 45–55 nm, increasing to 55–
70 nm after curcumin loading (Fig. 1B). The surface morpholog-
ical analysis of particles using atomic force microscopy (AFM)
showed significant projections, which might contribute to the
molecular recognition of particle by the receptor (Fig. 1C). The
proteinaceous nature of nanoparticle surface was confirmed by
their sensitivity to pH 5–6. Drug loading was 50% with 500 mgo f
curcumin/mg of protein upon complete saturation.
Cellular uptake of curcumin following nano-curcumin
administration
Cellular uptake of curcumin upon incubation with nano-
curcumin was monitored by confocal microscopic analysis of the
compound’s intrinsic green fluorescence. Intracellular localization
of curcumin was enhanced in nano-curcumin treated cells
compared to those treated with soluble-curcumin (Fig. 2A ii and
iii), indicating that apotransferrin encapsulation significantly
increases cellular uptake of curcumin. The curcumin localization
in overall population of SUPT1 cells was given in Fig. S1. To
determine whether the enhanced uptake of apotransferrin-
encapsulated curcumin requires interaction with the transferrin
receptor, we incubated the cells concurrently with nano-curcumin
and antibody to the human transferrin receptor. The observed
decrease in intracellular curcumin fluorescence (Fig. 2A iv)
suggests that nano-curcumin uptake results from endocytosis
mediated by the transferrin receptor. Similar results were seen
when intracellular curcumin accumulation was quantified fluor-
imetrically in experiments conducted with SUPT1 and stimulated
PBMCs (Fig. 2B). These results confirm that cellular uptake of
curcumin is significantly enhanced by apotransferrin encapsula-
tion and that this improved uptake is mediated by the transferrin
receptor in both SUPT1 (Fig. 2B i) and PBMCs (Fig. 2B ii).
Cellular retention of curcumin following nano-curcumin
administration
Cellular uptake and elimination of curcumin upon treatment
with sol- or nano-curcumin (1 and 10 mM) was assessed by
confocal microscopic analysis at different time points (1, 2, 4 and
6 h respectively). Soluble-curcumin was taken up quickly by the
cells, peaking at 2 h, but was rapidly eliminated out and was
essentially gone by 4 h (Figs. 3 and 4). Nano-curcumin, by contrast
was both taken up and released more slowly with a peak at 4 h and
,50% of the drug still present at 6 h (Figs. 3 and 4). Further, the
results confirmed that nano-cucumin exhibits a time-dependent
intracellular localization of curcumin (in both SUPT1 cells
PBMCs) that is stable for almost the full 6 h. In contrast,
soluble-curcumin is taken up rapidly, especially at the higher
concentration but disappeared from the cells quickly. This gradual
and stable uptake of nano-curcumin is characteristic of receptor-
mediated transport. Moreover, it is important to note that uptake
at 2 h is similar for the 1 and 10 mM concentrations of nano-
curcumin (Figs. 3 & 4 A and B) while uptake is significantly higher
for 10 mM than for 1 mM nano-curcumin at 6 h (Figs. 3 & 4 A and
B).
These results indicate that cells retain curcumin for longer
periods following treatment with nano-curcumin than with sol-
curcumin.
Cytotoxicity of nano-curcumin mediated delivery
To determine the relative cytotoxicity of curcumin in the nano-
curcumin and sol-curcumin formulations, SUPT1 cells (Fig. 5A) or
stimulated PBMCs (Fig. 5B) were incubated with increasing
concentrations (1, 5, 10, 25, 50 and 100 mM) of the two
formulations and cell survival was estimated by MTT assay. Both
sol- and nano-curcumin formulations were found non-toxic at very
low concentrations (1, 5 and 10 mM). However, 25 mM concen-
tration of sol-curcumin was extremely cytotoxic (almost 80%)
while nano-curcumin at the same concentration was significantly
less cytotoxic (Fig. 5). The GI50 of sol-curcumin is 15.6 mM, while
that of nano-curcumin it is 32.5 mM in SUPT1 cells. In stimulated
PBMCs, the GI50 is 18 mM for sol-curcumin and 38 mM for nano-
cucumin. The low cytotoxicity of nano-curcumin highlights the
observation that direct sol-curcumin administration is lethal to
cells at concentrations above 10 mM. Notably, decreased cytotox-
icity of apotransferrin encapsulated formulation occurred despite
increased cellular uptake and sustained retention.
HIV-1 neutralizing activity of nano-curcumin
SUPT1 cells or stimulated PBMCs were infected with HIV-
193IN101 in the presence of increasing concentrations (1, 2.5, 5, 10,
20 and 30 mM) of nano-curcumin or sol-curcumin. Nano-
curcumin inhibited HIV-1 replication in a dose-dependent
manner (Figs. 6A and 6C). The IC50 of nano-curcumin is
1.75 mM, while that of sol-curcumin it is 5.1 mM in SUPT1 cells.
In stimulated PBMCs, it is 5.1 mM for sol-curcumin and 2.4 mM
for nano-curcumin. These data suggest that nano-cucumin is
almost three-fold more potent than sol-curcumin. About 80%
inhibition of HIV-1 replication was estimated at 10 mM nano-
curcumin (Fig. 6A & C), a concentration at which its cytotoxicity is
less than 10% (Figs. 5 A and B). Although sol-curcumin exhibits a
75% inhibition of viral replication at this concentration, its
cytotoxicity is 20%. The HIV-1 neutralizing activity of nano-
curcumin is significantly reduced by antibody to human transferrin
receptor in both SUPT1 cells (Fig. 6B) and PBMCs (Fig. 6D),
confirming that the superior ability of nano-curcumin to inhibit
HIV-1 infection is dependent on cellular uptake mediated by the
transferrin receptor.
Effect of nano-curcumin on the expression of
topoisomerase IIa and proviral DNA synthesis
To determine the mechanism of nano-curcumin’s anti-HIV
activity in T-cells, we monitored expression of the human topoisomerase
IIagene. SUP-T1 cellswere acutely infected with HIV-193IN101 in the
presence of 5 mM nano-curcumin, sol-curcumin or appropriate
Anti-HIV Curcumin Nanoformulation
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expression demonstrated that this gene was upregulated on HIV
infection but was prominently down-regulated by nano-curcumin
treatment (Fig. 7A). This down-regulation was not observed when the
cells were treated with sol-curcumin. In a different experiment, it was
found that nano-curcumin significantly inhibited proviral DNA
synthesis, monitored by gag gene expression (Fig. 7B). Sol-curcumin
had no effect on synthesis of proviral DNA.
Figure 1. Curcumin loading increases size of apotransferrin nanoparticles. The preparations of curcumin-loaded apotransferrin
nanoparticles (nano-curcumin; left) and apotransferrin nanoparticles without curcumin (nano-apotransferrin; right) were examined by A) TEM B) SEM
and C) AFM as indicated.
doi:10.1371/journal.pone.0023388.g001
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inflammatory response
HIV-1 infection enhanced expression of topoisomerase IIb, IL-1b
and COX-2. Treatment of infected cells with nano-curcumin
significantly inhibited expression of IL-1b and COX-2 (Fig. 8) as
well as topoisomerase IIa (Fig. 7), but had no effect on the expression
of topoisomerase IIb or TNF-a (Fig. 8). The results are further
confirmed by estimation of IL-1b (Fig. 8B), COX-2 (Fig. 8C) and
TNF-a (Fig. 8D) levels in infected cells. These results suggest that
nano-curcumin effectively blocks HIV-1-mediated inflammatory
responses [21] and thus affects viral cDNA synthesis.
Discussion
Results reported here show that curcumin-loaded apotransferrin
forms spherical nanoparticles consistently in the size range 55–
70 nm, which is in accord with the National Nanotechnology
Initiative’s definition of ‘‘nanomaterials’’. Other reported formu-
lations have typically been larger in size (usually 100–200 nm)
[15,22], although Bisht et al. reported a polymeric nanoparticle
formulation with a size range similar to ours [23]. The spherical
shape and surface characteristics of the nanoparticles, as shown by
our TEM study, probably play a critical role in the cellular uptake
and release characteristics displayed by this curcumin formulation
in vitro. These particles are efficiently transported into cells through
endocytosis mediated by the transferrin receptor [19], with the
curcumin then being released intracellularly. Although a curcumin
derivative, EF24, has been chemically linked to an endocytosis-
inducing peptide [24], our nano-curcumin is to the best of our
knowledge the first formulation in which cellular uptake of
curcumin itself is enhanced by receptor-mediated endocytosis. The
nano-curcumin formulation is especially attractive because of its
simple preparation protocol that does not require either complex
equipment or expensive reagents. Moreover, this delivery system is
highly target-specific [19]. The simplicity of the preparation would
also minimize the possibility of potentially toxic reagents being
carried over into formulations for future in vivo studies.
Curcumin is naturally fluorescent in the visible green spectrum,
thus allowing it to be located and quantified within cells. Cells
treated with both sol- and nano-curcumin displayed green
fluorescence, confirming successful intracellular delivery of
curcumin. The greater cellular uptake and retention exhibited
by nano-curcumin, as demonstrated here, addresses the problem
of curcumin bioavailability. The ability of nanoparticle prepara-
Figure 2. Nanoparticle formulation increases curcumin uptake, which is inhibited by transferrin receptor blockade. A) SUP-T1 cells
were incubated for 1 h with curcumin formulations as indicated, then examined by confocal microscopy. (i) Cells without curcumin; (ii) 1 mM sol-
curcumin; (iii) 1 mM nano-curcumin; or (iv) 1 mM nano-curcumin in the presence of transferrin receptor antibody (100 ng/ml). Each panel contains
three images: fluorescence, bright field and merged. B) SUP-T1 cells (i) or stimulated PBMCs (ii) were incubated for 1 h with curcumin formulations,
after which intrinsic fluorescence of intracellular curcumin was determined quantitatively by fluorometric analysis. Cells were treated with 5 mM sol-
curcumin, 5 mM nano-curcumin, or 5 mM nano-curcumin in the presence of antibodies to the transferrin receptor (TrR-Ab; 100 ng/ml). All the values
are normalized to that obtained from SUPT1 cells. Error bars indicate standard deviation (SD). ***, P#0.001 compared to sol-curcumin; n.s.: non-
significant.
doi:10.1371/journal.pone.0023388.g002
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demonstrated by other groups [22,23]. Since cytotoxicity is of
prime concern for cellular assays, we performed our uptake and
retention studies at nano-curcumin concentrations that are non-
toxic to cells. Further studies showed that, despite greater
intracellular concentrations, nano-curcumin exhibited much less
cytotoxicity than equivalent doses of sol-curcumin.
Studies cited in the introduction demonstrate that curcumin is
extremely safe and will be tolerated at dosages up to 12 g/day. This
leads to the presumption that nano-curcumin will also be safe even
at high concentrations, On the other hand, high-dosage AZT can
cause myopathy, cardiomyopathy and hepatotoxicity associated
with mitochondrial DNA depletion. As a component of HAART
(highly active antiretroviral therapy) AZT causes cytopenias and
lipodystrophy [25–29]. Similar dose-limiting adverse effects are not
expected for curcumin. The present study addresses the major
problem of metabolic instability and shows that nano-curcumin,
even at relatively low concentrations provide a highly stable and
retarded release, leading to prolonged intracellular accumulation.
This prolonged exposure will reduce the needed concentration and
thus the cytotoxicity, while retarded release allows longer half-life.
Studies showing that curcumin has anti-viral properties are few but
reliable [30–32]. We now show that nano-curcumin, but not sol-
curcumin, has high anti-HIV activity. Nano-curcumin drastically
decreased expression levels of topoisomerase IIa and inhibited proviral
DNA synthesis. The high levels of intracellular curcumin achieved
through nano-curcumin administration may account for this
previously unreported observation. Curcumin has been previously
demonstrated to inhibit HIV activation and replication [30–33].
Mechanisms involved include inhibition of both HIV protease [32]
and integrase [34]. Curcumin also inhibits Tat-mediated transactiva-
tion of the HIV long terminal repeat, which is essential for activation
of latent virus [30,31]. Another mechanism may involve inhibition of
the virus’s ability to upregulate the host enzyme topoisomerase II
[35], which is required at the earliest stages of virus replication.
Repression of topoisomerases using an inhibitor [31] or antisense
nucleotides [36] results in impaired HIV-1 replication. Additionally,
Topoisomerase II naturally recognizing DNA topological intermedi-
ates such as DNA curvature, flexibility, rigidity and distortion greatly
influencethe HIV integration event [37,38]. Moreover, curcumin has
been shown to form a complex with DNA and topoisomerase,
producing DNA breaks and blocking their repair, much as etoposide
Figure 3. Nanoparticle formulation exhibits increased cellular retention in SUP-T1 cells. Cells were incubated with 1 mM (Panel A) and
10 mM (Panel B) sol-curcumin and nano-curcumin and examined by confocal microscopy at time points of 1, 2, 4 and 6 h. Each panel contains three
images: fluorescence, bright field and merged.
doi:10.1371/journal.pone.0023388.g003
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levels could predictably alter the HIV-1-mediated inflammatory
response, which may in turn affect the topological reorganization of
cellular DNA promoted by topoisomerase IIa.T h e s ee f f e c t so nD N A
organization might then prevent the HIV-1 integration event. This
explains the inhibition of proviral DNA synthesis, monitored through
gag gene expression, and the consequent blockage of HIV-1
replication observed in the current study.
In summary, the ability ofcurcumintoblockHIVreplication and
activation at several stages is well established. However, clinical use
has been hampered by the absence of an effective dosage regime.
Curcumin-loaded apotransferrin nanoparticles, through their
ability to target an endocytosis-promotingcellular receptor,increase
cellular uptake of the drug and enhance its ability to inhibit HIV-1
replication while simultaneously reducing cytotoxicity. Further
studies using relevant in vivo experimental models are required.
Nevertheless, this formulation appears promising as a step toward
clinical usage as a multivalent antiretroviral of this well-known but
underutilized therapeutic agent.
Materials and Methods
Preparation of stimulated PBMCs
Human blood was obtained from a healthy donor as per the
approval of the Institutional Ethics Committee, University of
Hyderabad. Human Peripheral blood mononuclear cells (PBMC)
were isolated from blood by density gradient centrifugation using
Histopaque-1077 (Sigma-Aldrich) and the cells were cultured in
RPMI 1640 medium (GIBCO-BRL) supplemented with 10%
FBS. PBMCs were stimulated using 10 mg/ml phytohemaggulu-
tinin (PHA) (Sigma-Aldrich) for 2 days in the presence of IL-2
(20 IU/ml; Sigma-Aldrich) in 5% CO2 at 37uC. Cells were
washed after 2 days and continued in culture with IL-2 for another
24 h and were stored at 270uC till further use.
Nanoparticle preparation
Nanoparticles were prepared using a variation of the
procedure described previously [19]. Ten mg of apotransferrin
(Sigma-Aldrich) in 100 ml of phosphate-buffered saline (pH 7.4)
Figure 4. Nanoparticle formulation exhibits increased cellular retention in stimulated PBMCs. Cells were incubated with 1 mM (Panel A)
and 10 mM (Panel B) sol-curcumin and nano-curcumin and examined by confocal microscopy at time points of 1, 2, 4 and 6 h. Each panel contains
three images: fluorescence, bright field and merged.
doi:10.1371/journal.pone.0023388.g004
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100 ml DMSO (100 mM) and the mixture was incubated on ice
for 5 min. The mixture of apotransferrin and curcumin was
slowly added to 15 ml of olive oil at 4uC with continuous
dispersion by gentle manual vortexing. The sample was
sonicated 15 times at 4uC using a narrow stepped titanium
probe of ultrasonic homogenizer (300V/T, Biologics Inc.,
Manassas, Virginia, USA). The sonication amplitude was 5 mm
and the pulses were 30 sec long with an interval of 1 min
between successive pulses. The resulting mixture was immedi-
ately frozen in liquid nitrogen for 10 min and was then
transferred to ice and incubated for 4 h. The particles formed
were pelleted by centrifugation at 6000 rpm for 10 min and the
pellet was extensively washed with diethyl ether and dispersed in
PBS. The particles’ protein content was estimated by the Biuret
method and the protein content was used to determine the
amount of nanoparticles used for each experiment.
Characterization of nanoparticles
Structure and morphology of the nanoparticles were investigat-
ed using a scanning electron microscope (SEM, Philips FEI-XL 30
ESEM; FEI, Hillsboro, OR, USA) operated at 20 KV,
transmission electron microscope (TEM, Techni) operated at 80
KV and atomic force microscope (AFM; SPM400). For SEM the
particles were gold coated, the TEM sample was prepared by
fixing the sample on 200 mesh type-B carbon coated copper grid
(ICON) using 2% osmium tetroxide in 50 mM phosphate buffer
followed by staining with phosphotungstic acid, and the AFM
sample was spin coated on a glass cover slip. Manufacturer’s
instructions were followed for data collection, and analysis of
particles.
Nanoparticle localization assay
SUPT1 cells obtained from the NIH-AIDS Reference and
Reagents Program were used [40]. (1610
6) SUPT1 cells or
Figure 5. Nanoparticle formulation decreases curcumin cytotoxicity. SUPT1 cells (Panel A) or stimulated PBMCs (Panel B) were exposed to
increasing concentrations (1, 5, 10, 25, 50 and 100 mM) of sol-curcumin, nano-curcumin, azidothymidine (AZT) or nano-apotransferrin (10, 50 and
100 mg) for 16 h, after which cell viability was determined by MTT assay. PBMCs were cultured in the presence of IL-2 (20 IU/ml). Cell viability in the
absence of drug was defined as 0% cytotoxicity. Error bars indicate SD. ** P#0.01, and ***, P#0.001 compared to nano-curcumin. * indicates mg
apotransferrin protein that carry equivalent molar concentration of the drug.
doi:10.1371/journal.pone.0023388.g005
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Lifesciences) and treated with curcumin, either soluble or
incorporated into nanoparticles at 1 and 10 mM concentrations
and the cells were incubated at different time points (1, 2, 4 and
6 h). After incubation, the cells were washed thrice with
phosphate-buffered saline (pH 7.4) and observed under the laser
confocal microscope to analyse the amount of intracellular
curcumin employing the intrinsic fluorescence of curcumin (lEx
458 nm and Em 530 nm).
Competition of transferrin receptor antibodies with the
apotransferrin-drug nanoparticles
Cells (1610
6) were incubated in serum-free medium for 60 min
in a 12-well plate. Nano-curcumin or sol-curcumin (equivalent to 1
or 5 mM curcumin) was added to the cells in either the presence or
absence of 400 ng/ml monoclonal anti-human transferrin recep-
tor antibody (Calbiochem) and incubated for 2 h. After incuba-
tion, cells were washed thrice with phosphate-buffered saline
(pH 7.4) and lysed by sonication in lysis buffer (0.1% Triton-X-
100). The lysate was cleared by centrifugation at 12,000 rpm for
20 min at 4uC. Curcumin was quantified through its intrinsic
fluorescent emission (l Ex 458 nm and Em 530 nm) as measured
by a fluorescence spectrometer (Shimadzu FL 2000; Shimadzu,
Kyoto, Japan). In parallel, the cells were observed under a laser
confocal microscope. Experiments using stimulated PBMCs were
conducted in the presence of IL-2 (20 IU/ml).
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium
bromide (MTT) assay
SUPT1 cells or stimulated PBMCs (0.2610
6/well) were seeded
in a 96-well plate and incubated at 37uC for 4 h in a 5% CO2
incubator (Forma Scientific, Marietta, OH, USA). These cells
Figure 6. Nano-curcumin more effectively inhibits HIV-1 replication through a mechanism dependent on transferrin receptor. A&C )
SUPT1 cells (Panel A) or stimulated PBMCs (Panel C) were challenged for 2 h with HIV-193IN101 (1 mg p24/ml) in the presence of increasing
concentrations (1, 2.5, 5, 10, 20 and 30 mM) of sol-curcumin, nano-curcumin, or nano-apotransferrin (10 and 50 mg). They were then incubated for a
further 96 h, after which viral replication was measured by p24 antigen capture assay. *indicates mg apotransferrin protein that carry equivalent molar
concentration of the drug. B & D) SUP-T1 cells or stimulated PBMCs were challenged for 2 h with HIV-193IN101 in the presence of 2.5 or 5.0 mM
concentrations of sol-curcumin, nano-curcumin or nano-curcumin in the presence of transferrin receptor antibody (100 ng/ml). After 96 h incubation,
viral replication was measured by p24 antigen capture assay. In both these experiments, viral replication in the absence of drug was defined as 0%
inhibition; Azidothymidine (AZT) was employed as a positive control. Error bars indicate SD. ** P#0.01, and ***, P#0.001 compared to sol-curcumin;
n.s.: non-significant.
doi:10.1371/journal.pone.0023388.g006
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soluble or incorporated into nanoparticles (nano-curcumin was
assessed by the amount of associated protein), and incubated for
16 h. The cells were pelleted at 1200 rpm for 10 min and
resuspended in new medium. To this, 20 ml of 5 mg/ml MTT
(Sigma-Aldrich) was added and incubated for 4 h. The cells were
then pelleted at 1200 rpm for 20 minutes, the medium was
removed, and the precipitate was dissolved in DMSO and read in
an ELISA microplate reader at 570 nm.
HIV-1 neutralization assay
SUPT1 cells or stimulated PBMCs (0.4610
6/ml) with 100%
viability were seeded in RPMI 1640, 0.1% FBS on four 12-well
plates. Increasing concentration of nano-curcumin, sol-curcumin,
or nano-curcumin in the presence of anti-human transferrin
receptor antibody (as indicated) were added to the cells which were
then infected with HIV-193IN101 at a final virus concentration
equivalent to 1 ng of p24 per ml. The infected cells were incubated
for 2 h at 37uC in a 5% CO2 incubator. The cells were then
pelleted at 3506g for 10 min, the supernatant was discarded, and
cells were washed with RPMI 1640 containing 10% FBS. The
SUP-T1 cells were resuspended in fresh complete medium and
were incubated for a further 96 h. PBMCs were incubated for 7
days. The supernatants were then collected and analyzed using a
p24 antigen capture assay kit (Advanced Bioscience Laboratories,
Kensington, MD, USA). The extent of infection in the absence of
test compound was considered to be equivalent to 0% inhibition.
Azidothymidine (AZT) was employed as a positive control.
Experiments using stimulate PBMCs were conducted in the
presence of IL-2 (20 IU/ml).
qPCR analysis of topoisomerase IIa and gag expression
and semi-quantitative PCR analysis of topoisomerase IIb,
COX-2, IL-1b and TNF-a expression
Genomic DNA (to monitor gag expression) and total RNA were
isolated from treated samples using suppliers’ (Qiagen, GmbH,
Germany & Sigma-Aldrich respectively) protocol. cDNAs were
synthesized using Superscript
TM III first strand synthesis system
(Invitrogen, Carlsbad, CA, USA). Primers were designed based on the
gene sequences available in PUBMED nucleotide database. Multiple
alignment (wherever required) was performed using the ClustalW
program. For each gene, sequences of the forward and reverse primers
Figure 7. Inhibition of HIV-1 replication by nano-curcumin is due to abolished viral cDNA synthesis and/or altered topology. SUPT1
cells were challenged for 4 h with HIV-193IN101 in the presence of 5 mM of sol-curcumin, nano-curcumin or nano-apotransferrin. A) The expression of
topoisomerase IIa was determined by (i) semi-quantitative and (ii) quantitative-PCR. B) Quantity of viral cDNA synthesized was shown by both (i)
semi-quantitative and (ii) real-time PCR using gag-specific primers. Template from normal SUP-T1 cells was used as negative control. Azidothymidine
(AZT) was employed as a positive control and 18S was used as an internal control in both experiments. Error bars indicate SD. ***, P#0.001 compared
to sol-curcumin.
doi:10.1371/journal.pone.0023388.g007
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GCAGGGCCTATTGCACCAGGC 39, gag Rev: 59 GGCCAG-
GTCCTCCCACTCCC 39; topo IIa Fwd: 59 GGGTTCTTGA-
GCCCCTTCACGA 39, topo IIa Rev: 59 GTAGGTGTCTGGGCG-
GAGCAA 39; 18S Fwd: 59 GCTACCACATCCAAGGAAGG-
CAGC 39, 18S Rev: 59 CGGCTGCTGGCACCAGACTTG 39; topo
IIb Fwd: 59 GCCCAGTTGGCTGGCTCTGT 39, topo IIb Rev: 59
GCATGGGATGAGGATCCAGGCC; COX-2 Fwd: 59 AACAG-
GAGCATCCTGAATGG 39, COX-2 Rev: 59 GGTCAATG-
GAAGCCTGTGATG 39; IL-1b Fwd: 59 AGCTGATGGCCC-
TAAACAGA 39, IL-1b Rev: 59 TCTTTCAACACGCAGGACAG
39; TNF-a Fwd: 59 AGCCCATGTTGTAGCAAACC 39, TNF-a
Rev: 59 CCAAAGTAGACCTGCCCAGA 39. Real-time PCR was
performed on an ABI PrismH 7500 fast thermal cycler (Applied
Biosystems, Foster, CA, USA). Each sample was run in triplicate in a
final volume of 25 ml containing 1 ml of template (1:10 dilution),
10 pmol of each primer and 12 ml of Power SYBRH Green PCR
master mix (Applied Biosystems).T h er e a l - t i m eP C Rr e s u l t sw e r e
presented as change in expression relative to control using target gene
CT values normalized to that of 18S gene CT values based on the
comparative CT method [41].
IL-1 b, PGE2 and TNF a assays
Cells (1610
5) were treated with either HIV, nano-curcumin,
AZT, soluble-curcumin or apotransferrin for 4 h. Levels of IL-1b,
PGE2 and TNF-a in the culture media were quantified using
ELISA kits (R&D Systems, Minneapolis, MN, USA). The protocol
was followed as per the manufacturer’s instructions.
Statistical analysis
Statistical analyses were performed using SPSS Statistics 16 (SPSS,
Chicago, IL). Data are presented as mean 6 S.D. Differences between
groups were evaluated using Students’s t test or one-way analysis of
variance (ANOVA) with Tukey’s post-hoc analysis. All experiments
were repeated three times, unless otherwise specified. Values of P,0.05
were considered to be statistically significant.
Supporting Information
Figure S1 Data in Figure 2 presented in a population of
cells to show overall curcumin localization in a popula-
tion of cells.
(TIF)
Figure 8. Action of nano-curcumin against virus-induced inflammatory response. A) SUPT1 cells were challenged for 4 h with HIV-193IN101
in the presence of 5 mM of sol-curcumin, nano-curcumin or nano-apotranferrin. The expression of topoisomerase IIb, IL-1b, TNF-a and COX-2 was
determined by semi-quantitative-PCR. Template from normal SUP-T1 cells was used as negative control. 18S was used as an internal control in both
experiments. IL-1b (Panel B), COX-2 (Panel C) and TNF-a (Panel D) were estimated using commercial kits as described in the methods section. Error
bars indicate SD. ***, P#0.001 compared to nano-curcumin.
doi:10.1371/journal.pone.0023388.g008
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